Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Efficacy Week 16 results As reported previously, secukinumab 150 mg significantly improved all prespecified end points at week 16 versus placebo, except ASAS partial remission; the 75‐mg dose did not reach statistical significance at week 16 for the primary end point or any prespecified secondary end points based on hierarchical hypothesis testing 20 .

also in 111,027 other papers